Development
Biodesix, Inc.
BDSX
$0.3029
$0.02117.49%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 52.68% | 21.46% | 8.42% | 38.30% | 32.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.68% | 21.46% | 8.42% | 38.30% | 32.99% |
| Cost of Revenue | 2.06% | -11.12% | -18.64% | -2.04% | 32.61% |
| Gross Profit | 79.24% | 37.30% | 23.87% | 77.69% | 33.19% |
| SG&A Expenses | -2.26% | 2.53% | 9.29% | 31.08% | 22.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.44% | -4.85% | 0.99% | 21.41% | 24.30% |
| Operating Income | 50.71% | 32.40% | 6.01% | -13.72% | -18.93% |
| Income Before Tax | 55.06% | 20.07% | 15.60% | -19.99% | -53.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 55.06% | 20.07% | 15.60% | -19.99% | -53.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.06% | 20.07% | 15.60% | -19.99% | -53.12% |
| EBIT | 50.71% | 32.40% | 6.01% | -13.72% | -18.93% |
| EBITDA | 54.83% | 34.24% | 5.45% | -15.56% | -20.03% |
| EPS Basic | 71.86% | 59.43% | 57.82% | 52.05% | 28.32% |
| Normalized Basic EPS | 65.12% | 59.27% | 48.15% | 51.88% | 41.90% |
| EPS Diluted | 71.86% | 59.43% | 57.82% | 52.05% | 28.32% |
| Normalized Diluted EPS | 65.12% | 59.27% | 48.15% | 51.88% | 41.90% |
| Average Basic Shares Outstanding | 59.72% | 97.07% | 100.07% | 150.29% | 113.59% |
| Average Diluted Shares Outstanding | 59.72% | 97.07% | 100.07% | 150.29% | 113.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |